pharma news

May 05, 2020

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...

Apr 30, 2020

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...

Apr 23, 2020

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Apr 21, 2020

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Apr 16, 2020

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...

Apr 14, 2020

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Apr 09, 2020

AstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...

Apr 02, 2020

Niacin might help in combating Glioblastoma  Glioblastomas are difficult to treat in part as the brain’s immune cells are stifled and unable to attack against tumors. A research team of the University of Calgary in Canada revealed that a common vitamin might help resolve the issue. The researchers presen...

Mar 31, 2020

Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19.  The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...

Mar 26, 2020

FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...